Abstract
Adult T-cell leukemia/lymphoma (ATLL) develops in elderly individuals who have been infected with human T-cell leukemia virus type 1 (HTLV-1), and the prognosis for patients with ATLL has been extremely poor. Retrospective studies of allogeneic stem cell transplantation (alloSCT) for selected populations of patients have achieved several encouraging results; however, the reported incidence of transplantation-related mortality (TRM) have been high, even though more than 80% of patients received stem cells from related donors and the patients were relatively young for ATLL. This report documents a prospective feasibility study of alloSCT with reduced-intensity conditioning (RIST) for elderly ATLL patients (>50 years). Regimen-related toxicities and nonhematologic toxicities were acceptable. Fourteen of 15 evaluable patients achieved complete donor chimerism within 90 days, and 1 patient had early TRM after RIST. The HTLV-1 proviral load became undetectable in 8 of 15 patients, suggesting that RIST has potential as an antiviral treatment. The results of alloSCT are promising, and 30% to 40% of patients who achieve remission and have suitable donors can now become long-term survivors with either conventional alloSCT or RIST. It is clear that a graft-versus-ATLL effect is present after alloSCT, regardless of the conditioning regimen or the stem cell source.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tsukasaki K, Maeda T, Arimura K, et al. Poor outcome of autolo- gous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature.Bone Marrow Transplant. 1999;23:87–89.
Yamada Y,Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia- lymphoma: Japan Clinical Oncology Group Study 9303.Br J Haematol. 2001;113:375–382.
Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant. 2001;27:15–20.
Kami M, Hamaki T, Miyakoshi S, et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma.Br J Haematol. 2003;120:304–309.
Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hematopoietic stem-cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma.Leukemia. 2005; 19:829–834.
Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/ lymphoma.Blood. 2005;105:4143–4145.
The Japan Society for Hematopoietic Cell Transplantation.Annual Report of Nationwide Survey 2006. Nagoya, Japan: The Japan Society for Hematopoietic Cell Transplantation Office of Nationwide Survey; 2006.
Sobue R, Yamauchi T, Miyamura K, et al. Treatment of adult T cell leukemia with mega-dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation.Bone Marrow Transplant. 1987;2:441–444.
Tamaki H, Matsuoka M. Donor-derived T-cell leukemia after bone marrow transplantation.N Engl J Med. 2006;354:1758–1759.
Nakase K, Hara M, Kozuka T, et al. Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/ lymphoma.Bone Marrow Transplant. 2006;37:41–44.
Kato K, Kanda Y, Eto T, et al. Allogeneic bone marrow transplantation from unrelated HTLV-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program.Biol Blood Marrow Transplant. 2007; 13:90–99.
Wake A, Kato D, Takagi S, et al. Reduced-intensity cord blood transplantation (RICBT) is a feasible approach for advanced adult T-cell leukemia (ATL) [abstract].Blood. 2005;106. Abstract 5448.
Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.Blood. 1998;91:756–763.
Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.J Clin Oncol. 1998;16:2817–2824.
Sonoda J, Koriyama C, Yamamoto S, et al. HTLV-1 provirus load in peripheral blood lymphocytes of HTLV-1 carriers is diminished by green tea drinking.Cancer Sci. 2004;95:596–601.
Abe Y, Yashiki S, Choi I, et al. Eradication of virus-infected T-cells in a case of adult T-cell leukemia/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin.Int J Hematol. 2002;76:91–93.
Harashima N, Kurihara K, Utsunomiya A, et al. Graft-versus- humanTax response in adult T cell leukemia patients after hemato- poietic stem cell transplantation.Cancer Res. 2004;64:391–399.
Kannagi M, Harashima N, Kurihara K, et al. Tumor immunity against adult T-cell leukemia.Cancer Sci. 2005;96:249–255.
Fujiwara H, Kawada H, Matsushita K, et al. Case of a patient with progressive adult T-cell leukemia/lymphoma treated successfully by reduced-intensity conditioning stem cell transplantation from an HLA-incompatible related donor.Int J Hematol. 2005;82:357–361.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Okamura, J., Uike, N., Utsunomiya, A. et al. Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma. Int J Hematol 86, 118–125 (2007). https://doi.org/10.1532/IJH97.07070
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1532/IJH97.07070